2 minute read | May.17.2023
The Company
Resurrect Bio, a biotech startup that uses gene editing to protect crops from disease, has completed a seed investment round that will fuel the next stage of its growth.
Orrick advised London-based Resurrect Bio on the £1.6 million round.
Plant breeders have bred crops over generations to improve traits like yield, height or drought-tolerance, the company says, but some crops have lost key immune resistance genes – R-genes. Resurrect Bio says it combines computational biology, artificial intelligence and synthetic biology methods “to resurrect R-genes to give our crops the tools to defend themselves again.”
The Impact
The investment will help Resurrect Bio make strides toward sustainable agriculture.
“Resurrect Bio is thrilled to have secured this investment from such a strong group of partners who share our vision of delivering disease-resistant crops to farmers,” said Dr. Cian Duggan, the company’s CEO and co-founder.
The company is building a platform that leverages gene-editing techniques to “fix the innate immune system of crops and make crops more resistant to disease.” That could help farmers increase yields and decrease their use of agrichemicals.
“With this new investment, Resurrect Bio will accelerate product development and strengthen its underlying disease resistance trait-discovery platform,” the company said.
The Team
The London-based team that advised Resurrect Bio on this transaction was led by Jamie Moore, Stephen Tallon, Rachel Conder and Joel Othen-Lawson.
Learn More
Resurrect Bio
Resurrect Bio news release (on LinkedIn)
Read More Orrick Client Results